No Data
Minsheng Securities: The advantages of CGM real-time blood glucose monitoring are significant, with outstanding clinical value.
Driven by factors such as the deepening global aging population, the increasing demand for the diagnosis and treatment of diabetes patients, and the gradual improvement of the healthcare insurance system, the CGM industry will experience continuous growth.
MicroTech Medical-B (02235.HK) spent 0.1293 million Hong Kong dollars to repurchase 0.0223 million shares on December 24.
Glonghui announced on December 24 that Weitai Medical-B (02235.HK) spent HKD 0.1293 million to repurchase 0.0223 million shares on December 24, with a repurchase price of HKD 5.72-5.8 per share.
On December 20, 2023, MicroTech Medical-B (02235.HK) spent 0.293 million Hong Kong dollars to repurchase 0.0537 million shares.
Gelonghui reported on December 20 that Weitai Medical-B (02235.HK) announced that it spent 0.293 million Hong Kong dollars to repurchase 0.0537 million shares on December 20.
MicroTech Medical-B (02235.HK) spent 0.131 million Hong Kong dollars to repurchase 0.0256 million shares on December 18.
Gelonghui reported on December 18 that Weitai Medical-B (02235.HK) announced that on December 18, it spent 0.131 million Hong Kong dollars to repurchase 0.0256 million shares.
MicroTech Medical-B (02235.HK) repurchased 0.0119 million shares on December 17.
Gelonghui reported on December 17 that Weitai Medical-B (02235.HK) announced it spent 0.0589 million HKD to repurchase 0.0119 million shares on December 17, 2024, at a repurchase price of 4.95 HKD per share.
Weitai Medical-B (02235) invested 0.412 million Hong Kong dollars on December 12 to repurchase 0.0898 million shares.
Microtech Medical-B (02235) announced that on December 12, 2024, it spent 0.412 million Hong Kong dollars to repurchase...
